[go: up one dir, main page]

MX2015016760A - Derivados de ftalazina. - Google Patents

Derivados de ftalazina.

Info

Publication number
MX2015016760A
MX2015016760A MX2015016760A MX2015016760A MX2015016760A MX 2015016760 A MX2015016760 A MX 2015016760A MX 2015016760 A MX2015016760 A MX 2015016760A MX 2015016760 A MX2015016760 A MX 2015016760A MX 2015016760 A MX2015016760 A MX 2015016760A
Authority
MX
Mexico
Prior art keywords
phthalazine derivatives
diseases
tankyrase
inflammation
inhibitors
Prior art date
Application number
MX2015016760A
Other languages
English (en)
Other versions
MX369393B (es
Inventor
Dieter Dorsch
Hans-Peter Buchstaller
Christina Esdar
Birgitta Leuthner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2015016760A publication Critical patent/MX2015016760A/es
Publication of MX369393B publication Critical patent/MX369393B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/34Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los compuestos de la fórmula I en donde R1, X y n tienen los significados indicados en la reivindicación 1, son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
MX2015016760A 2013-06-24 2014-05-30 Derivados de ftalazina. MX369393B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003205 2013-06-24
PCT/EP2014/001467 WO2014206524A1 (en) 2013-06-24 2014-05-30 Phthalazine derivatives

Publications (2)

Publication Number Publication Date
MX2015016760A true MX2015016760A (es) 2016-04-13
MX369393B MX369393B (es) 2019-11-07

Family

ID=48698872

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016760A MX369393B (es) 2013-06-24 2014-05-30 Derivados de ftalazina.

Country Status (21)

Country Link
US (1) US9751842B2 (es)
EP (1) EP3013804B1 (es)
JP (1) JP6382964B2 (es)
KR (1) KR20160023854A (es)
CN (1) CN105339356B (es)
AR (1) AR096652A1 (es)
AU (1) AU2014301669B2 (es)
CA (1) CA2916557C (es)
DK (1) DK3013804T3 (es)
ES (1) ES2623704T3 (es)
HR (1) HRP20170291T1 (es)
IL (1) IL243252A0 (es)
LT (1) LT3013804T (es)
MX (1) MX369393B (es)
PL (1) PL3013804T3 (es)
PT (1) PT3013804T (es)
RS (1) RS55943B1 (es)
RU (1) RU2663623C2 (es)
SG (1) SG11201510584WA (es)
SI (1) SI3013804T1 (es)
WO (1) WO2014206524A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466965A (en) 1982-07-26 1984-08-21 American Hospital Supply Corporation Phthalazine compounds, compositions and use
IT1296984B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
HU228960B1 (hu) * 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
DE102004023507A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexylessigsäure-Derivate
AU2005259189B2 (en) 2004-06-30 2011-04-21 Janssen Pharmaceutica N.V. Phthalazine derivatives as PARP inhibitors
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE
JP2009286773A (ja) * 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類

Also Published As

Publication number Publication date
CN105339356A (zh) 2016-02-17
PL3013804T3 (pl) 2017-08-31
SI3013804T1 (sl) 2017-05-31
IL243252A0 (en) 2016-02-29
KR20160023854A (ko) 2016-03-03
HK1221468A1 (zh) 2017-06-02
JP2016523272A (ja) 2016-08-08
DK3013804T3 (en) 2017-04-10
SG11201510584WA (en) 2016-01-28
LT3013804T (lt) 2017-04-10
ES2623704T3 (es) 2017-07-12
HRP20170291T1 (hr) 2017-04-21
CN105339356B (zh) 2018-10-19
AU2014301669A1 (en) 2016-02-11
WO2014206524A1 (en) 2014-12-31
RU2663623C2 (ru) 2018-08-07
US9751842B2 (en) 2017-09-05
EP3013804A1 (en) 2016-05-04
CA2916557C (en) 2021-08-03
JP6382964B2 (ja) 2018-08-29
RS55943B1 (sr) 2017-09-29
PT3013804T (pt) 2017-05-08
RU2016102057A3 (es) 2018-03-16
MX369393B (es) 2019-11-07
US20160318876A1 (en) 2016-11-03
EP3013804B1 (en) 2017-02-01
RU2016102057A (ru) 2017-07-28
CA2916557A1 (en) 2014-12-31
AU2014301669B2 (en) 2018-03-01
AR096652A1 (es) 2016-01-27

Similar Documents

Publication Publication Date Title
MX362939B (es) Derivados de (aza-)isoquinolinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
MX2014013090A (es) Derivados de pirrolotriazinona.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
NZ720478A (en) Autotaxin inhibitor compounds
MX2016014436A (es) Derivados de heterociclil-butanamida.
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2015017964A (es) Inhibidores de bromodominio.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX366140B (es) Derivados de urea de piperidinas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
MX364859B (es) Derivados de imidazopirazinona.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX369393B (es) Derivados de ftalazina.
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
FG Grant or registration